European Council adopts decision extending the period under 'Article 50'
Following the European Council meeting on 22 March 2019, the date for UK's withdrawal from the EU has been extended beyond 30 March 2019.
Under the European Council decision, if the withdrawal agreement between the UK and the EU is approved by the UK House of Commons by 29 March 2019, the extension will be until 22 May 2019. If the withdrawal agreement is not approved by 29 March 2019, the extension will be until 12 April 2019. In that event, the UK will indicate a way forward before 12 April 2019, for consideration by the European Council.
The decision makes clear that the UK remains a Member State for the duration of the extension, with all the rights and obligations set out in the treaties and under EU law.
All pharmaceutical companies in the EU are reminded to continue their preparedness for the UK’s withdrawal.
Based on the European Council decision, the deadline of 29 March 2019 referred to in Brexit related guidance should be understood to be replaced by 12 April 2019 until further notice.
For more information, see:
Questions & answers: EU actions to prevent medicine shortages due to Brexit (link to EMA website)